Pulmonx Corporation (LUNG) Stock Forecast
LUNG analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.20 / 5 from 5 analysts
- Price target
- $3.40 average of analyst targets
- Upside to target
- +91.0% from the latest close
- Next earnings
- October 27, 2026 EPS estimate $-0.26
- 52-week range
- $1.17 – $2.60
LUNG analyst ratings
5 analystsNumber of analysts at each rating.
LUNG price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
LUNG earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.26 | −$0.28 | −$0.23 | −$0.34 | +24.7% | 5 |
| Current fiscal year (2026) | −$1.04 | −$1.09 | −$0.97 | −$1.33 | +21.5% | 5 |
| Next fiscal year (2027) | −$0.94 | −$1.08 | −$0.80 | −$1.04 | +9.8% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
LUNG revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $21.9M | $21.8M | $22.0M | +2.1% | 5 |
| Current fiscal year (2026) | $90.5M | $90.0M | $91.0M | +0.1% | 5 |
| Next fiscal year (2027) | $98.3M | $94.5M | $102.3M | +8.6% | 5 |
LUNG EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
LUNG revenue: reported and forecast
LUNG EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.28 | −$0.29 | −$0.29 | −$0.29 | −$0.26 | −9.1% | 4 up · 0 down |
| Current fiscal year (2026) | −$1.14 | −$1.14 | −$1.14 | −$1.14 | −$1.04 | −8.3% | 4 up · 0 down |
| Next fiscal year (2027) | −$0.89 | −$1.04 | −$1.04 | −$1.04 | −$0.94 | +5.5% | 4 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
LUNG earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; LUNG beat in 12 of 12.
What analysts expect from LUNG
5 analysts cover Pulmonx; their consensus rating is buy (4.20 on a 1–5 scale, where 5 is a strong buy). The average price target is $3.40, 91.0% above the latest close of $1.78. Analysts expect earnings of −$1.04 per share for 2026, +21.5% from a year earlier. For 2027 the average estimate is −$0.94 per share on revenue of $98.3 million. Pulmonx beat the EPS estimate in 12 of the last 12 quarters.
Related: LUNG income statement, LUNG key metrics, LUNG chart. See the LUNG stock overview for the latest quote and news.
LUNG forecast FAQ
What is Pulmonx's price target?
The average analyst price target for Pulmonx is $3.40, 91.0% above the latest close of $1.78.
Is Pulmonx a buy, hold or sell?
Of 5 analysts covering Pulmonx, 3 rate it a strong buy, 0 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Pulmonx's EPS forecast?
Analysts forecast −$1.04 per share for 2026 (range −$1.09 to −$0.97); for 2027 the estimate is −$0.94.
What is Pulmonx's revenue forecast?
The average revenue estimate for 2026 is $90.5 million, growth of 0.1%; for 2027 it is $98.3 million.
When does Pulmonx report earnings?
Pulmonx is expected to report results for the quarter ending September 30, 2026 on October 27, 2026 after the market closes; the EPS estimate is $-0.26.
Does Pulmonx usually beat earnings estimates?
Pulmonx reported EPS at or above the analyst estimate in 12 of the last 12 quarters.